Entera Bio (ENTX) Change in Accured Expenses (2021 - 2026)

Entera Bio (ENTX) has reported Change in Accured Expenses for 6 consecutive years, with -$2000.0 the latest figure, recorded in Q1 2026.

• Quarterly Change in Accured Expenses fell 100.23% year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156000.0 (down 85.3% YoY) and the FY2025 annual result came in at $1.0 million, up 414.29% from the prior year.
• Change in Accured Expenses retreated to -$2000.0 in Q1 2026 per ENTX's latest filing, from $204000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for ENTX reached as high as $886000.0 in Q1 2025 and fell as low as -$808000.0 in Q1 2022.
• A 5-year average of -$52117.6 and a median of $28000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses sank 2106.9% — and 2025, when it soared 3064.29%.
• Year by year, Change in Accured Expenses stood at $581000.0 in 2022, then sank by 213.94% to -$662000.0 in 2023, then surged by 147.13% to $312000.0 in 2024, then plunged by 34.62% to $204000.0 in 2025, then plunged by 100.98% to -$2000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$2000.0, $204000.0, and -$77000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.